1. What is the current size of the autoimmune disease testing market?
The global autoimmune disease testing market is valued at US$6.6 Billion in 2025, according to our primary research.
+1 2315155523
Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
Research Analyst


The global autoimmune disease testing market is undergoing a structural transformation, propelled by an escalating clinical burden and a decisive shift toward precision diagnostics. Our proprietary primary research estimates the market at US$6.6 Billion in 2025, with a clear trajectory to US$13.4 Billion by 2032, representing a robust CAGR of 10.8% over the forecast period. This growth is not merely a function of volume; it reflects a fundamental re-pricing of diagnostic value as healthcare systems recognize the long-term cost benefits of early, accurate autoantibody detection.
Historically, the market expanded at a 9.0% CAGR between 2019 and 2024, but the post-pandemic era has accelerated adoption of automated immunoassay platforms and multiplex panels. The addressable market is expanding beyond traditional hospital laboratories into specialty clinics, reference labs, and, increasingly, point-of-care settings. Our bottom-up modeling, validated through expert interviews with laboratory directors and procurement heads, indicates that consumables and reagents will remain the economic engine of the sector, while instruments increasingly commoditize.
The market is being reshaped by three converging forces: epidemiological reality, technological enablement, and economic necessity.
Drivers
Restraints
Opportunities
The autoimmune disease testing value chain is characterized by a high degree of integration among top-tier players, yet retains niches for specialized suppliers.
Our segmentation analysis reveals a market where localized autoimmune diseases and consumables dictate commercial strategy.
By Disease Type
By Product
By Test Type
The geographic distribution of the autoimmune disease testing market reflects both healthcare infrastructure maturity and rising disease awareness.
| Region | 2025 Market Share | Key Growth Drivers |
|---|---|---|
| North America | 37% | Advanced healthcare infrastructure, high awareness, favorable reimbursement, strong R&D investment |
| Europe | 26% | Government screening programs, aging population, collaborative research initiatives |
| Asia-Pacific | 24% | Rapidly growing awareness, government initiatives, expansion of diagnostic labs, point-of-care adoption |
| Latin America | 7% | Improving healthcare access, rising prevalence, but limited by cost constraints |
| Middle East & Africa | 6% | Increasing investment in healthcare, but infrastructure gaps persist |
North America remains the dominant market, accounting for nearly 37% of global revenue in 2025. The U.S. alone represents the largest single market, driven by the high prevalence of autoimmune disorders (affecting up to 50 million Americans) and the presence of leading diagnostic companies. The region is also at the forefront of adopting advanced technologies such as AI-assisted interpretation and multiplex panels.
Asia-Pacific is the fastest-growing region, with a projected CAGR exceeding 12% during the forecast period. Factors include rising awareness, government-led screening programs, and the increasing availability of rapid diagnostic kits. However, market penetration is hindered by low awareness in rural areas and limited reimbursement coverage.
Europe shows steady growth, supported by government initiatives and a strong focus on personalized medicine. The presence of major diagnostic companies and research consortia (e.g., the Autoimmunity Centers of Excellence) fosters innovation.
The competitive landscape is moderately consolidated, with the top five players—Abbott, Bio-Rad, Roche, Siemens Healthineers, and Thermo Fisher Scientific—collectively holding approximately 29.4% of the market in 2024. Roche leads with over 11.2% share, leveraging its broad immunoassay portfolio and global distribution.
Key strategies observed in our primary research include:
The market has witnessed several notable developments that underscore its dynamism:
Our analysis identifies several under-served areas with significant potential:
The autoimmune disease testing market is poised for a decade of robust growth, driven by epidemiological necessity and technological innovation. Stakeholders must navigate standardization challenges and cost pressures while capitalizing on the shift toward precision medicine and point-of-care solutions. Our proprietary data and expert insights indicate that companies investing in automation, multiplexing, and geographic expansion—particularly in Asia-Pacific—will be best positioned to capture the US$13.4 Billion market by 2032.
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 10.8% from 2020-2034 |
| Segmentation |
|
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
| Stakeholder Role | Interview Share (%) |
|---|---|
| Laboratory Director | 35% |
| Procurement Manager | 25% |
| R&D Scientist | 20% |
| Clinical Immunologist | 20% |
| Company Type | Representation (%) |
|---|---|
| In Vitro Diagnostics (IVD) Manufacturers | 30% |
| Specialty Diagnostic Reagent Suppliers | 25% |
| Hospital & Reference Laboratories | 20% |
| Contract Research Organizations (CROs) | 15% |
| Distributors & Channel Partners | 10% |
The global autoimmune disease testing market is valued at US$6.6 Billion in 2025, according to our primary research.
The market is expected to grow at a CAGR of 10.8% from 2025 to 2032, reaching US$13.4 Billion by 2032.
North America holds the largest share, accounting for approximately 37% of the global market in 2025, driven by high disease prevalence and advanced healthcare infrastructure.
Key drivers include the rising prevalence of autoimmune diseases, adoption of advanced diagnostic technologies such as multiplex immunoassays, and favorable reimbursement policies in developed regions.
Leading companies include Abbott, Bio-Rad, Roche, Siemens Healthineers, and Thermo Fisher Scientific, which collectively held a 29.4% market share in 2024.